BR112015012111A8 - formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas. - Google Patents

formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas.

Info

Publication number
BR112015012111A8
BR112015012111A8 BR112015012111A BR112015012111A BR112015012111A8 BR 112015012111 A8 BR112015012111 A8 BR 112015012111A8 BR 112015012111 A BR112015012111 A BR 112015012111A BR 112015012111 A BR112015012111 A BR 112015012111A BR 112015012111 A8 BR112015012111 A8 BR 112015012111A8
Authority
BR
Brazil
Prior art keywords
drug
preparation
powder mix
oral solutions
direct powder
Prior art date
Application number
BR112015012111A
Other languages
English (en)
Other versions
BR112015012111A2 (pt
Inventor
Henriquez Francisco
Campbell Gossett
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015012111(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015012111A2 publication Critical patent/BR112015012111A2/pt
Publication of BR112015012111A8 publication Critical patent/BR112015012111A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica". a presente invenção refere-se a formulações farmacêuticas inovadoras que contêm solvato de n-{3-[3-ciclopropil-5-(2-flúor-4-iodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetra-hidro-2h-pirido[4,3-d] pirimidin-1-il]fenil}acetamida dimetil sulfóxido, métodos de uso das composições em terapia e processos para a preparação das mesmas.
BR112015012111A 2012-11-30 2013-11-26 formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas. BR112015012111A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Publications (2)

Publication Number Publication Date
BR112015012111A2 BR112015012111A2 (pt) 2017-07-11
BR112015012111A8 true BR112015012111A8 (pt) 2018-01-23

Family

ID=50828398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012111A BR112015012111A8 (pt) 2012-11-30 2013-11-26 formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas.

Country Status (29)

Country Link
US (2) US20150328320A1 (pt)
EP (2) EP3400933A1 (pt)
JP (1) JP6232443B2 (pt)
KR (1) KR102206432B1 (pt)
CN (2) CN107970214A (pt)
AR (1) AR093648A1 (pt)
AU (1) AU2013352369B2 (pt)
BR (1) BR112015012111A8 (pt)
CA (1) CA2891346A1 (pt)
CL (1) CL2015001459A1 (pt)
EA (2) EA028246B1 (pt)
ES (1) ES2686730T3 (pt)
HK (1) HK1209047A1 (pt)
IL (3) IL300664A (pt)
IN (1) IN2015DN04094A (pt)
MA (1) MA38121A1 (pt)
MX (1) MX2015006867A (pt)
MY (1) MY170427A (pt)
NZ (1) NZ628395A (pt)
PE (1) PE20151024A1 (pt)
PH (1) PH12015501168A1 (pt)
PL (1) PL2925299T3 (pt)
PT (1) PT2925299T (pt)
SG (1) SG11201503688SA (pt)
TN (1) TN2015000198A1 (pt)
TW (2) TW201434468A (pt)
UY (1) UY35157A (pt)
WO (1) WO2014085371A1 (pt)
ZA (1) ZA201503346B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
US10709699B2 (en) 2016-11-25 2020-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2021081554A1 (en) * 2019-10-22 2021-04-29 Chemistryrx Methods for treating congenital epidermal hyperplasia
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) * 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
DK1819353T3 (da) * 2004-12-07 2011-05-16 Proteolix Inc Sammensætning til proteasomhæmning
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
DK2581078T3 (en) * 2005-10-26 2015-03-02 Cydex Pharmaceuticals Inc Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
NZ579098A (en) * 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
DK3560498T3 (da) * 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
CA2817287A1 (en) 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
CN103596957B (zh) * 2011-04-07 2016-12-07 拜耳知识产权有限责任公司 作为akt激酶抑制剂的咪唑并哒嗪
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
IN2015DN04094A (pt) 2015-10-09
JP2016501874A (ja) 2016-01-21
MA38121A1 (fr) 2016-10-31
EP2925299A4 (en) 2016-06-29
TW201434468A (zh) 2014-09-16
EP2925299B1 (en) 2018-06-06
IL238971B (en) 2019-05-30
IL300664A (en) 2023-04-01
ES2686730T3 (es) 2018-10-19
CL2015001459A1 (es) 2015-12-18
PT2925299T (pt) 2018-10-16
PL2925299T3 (pl) 2018-11-30
US20170189408A1 (en) 2017-07-06
EA028246B1 (ru) 2017-10-31
TN2015000198A1 (en) 2016-10-03
PH12015501168A1 (en) 2015-08-10
BR112015012111A2 (pt) 2017-07-11
MY170427A (en) 2019-07-31
CA2891346A1 (en) 2014-06-05
UY35157A (es) 2014-06-30
EP2925299A1 (en) 2015-10-07
EP3400933A1 (en) 2018-11-14
ZA201503346B (en) 2016-01-27
AU2013352369B2 (en) 2016-07-28
US20150328320A1 (en) 2015-11-19
NZ628395A (en) 2016-10-28
EA201791411A1 (ru) 2018-03-30
WO2014085371A1 (en) 2014-06-05
EA201591047A1 (ru) 2015-11-30
TW201831187A (zh) 2018-09-01
HK1209047A1 (en) 2016-03-24
IL266415B2 (en) 2024-03-01
SG11201503688SA (en) 2015-06-29
CN107970214A (zh) 2018-05-01
KR20150091352A (ko) 2015-08-10
IL266415B1 (en) 2023-11-01
CN104902876B (zh) 2018-01-19
KR102206432B1 (ko) 2021-01-22
AU2013352369A1 (en) 2015-05-28
CN104902876A (zh) 2015-09-09
AR093648A1 (es) 2015-06-17
IL266415A (en) 2019-06-30
MX2015006867A (es) 2015-10-05
JP6232443B2 (ja) 2017-11-15
PE20151024A1 (es) 2015-07-27
IL238971A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CY1123376T1 (el) Νεα φαρμακευτικη συνθεση
BR112015012111A8 (pt) formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas.
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
MX2013001677A (es) Formulaciones estables de linaclotida.
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
BRPI0820308B8 (pt) composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
IN2015DN01165A (pt)
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
PH12014502619A1 (en) Novel dosage and formulation
MY185947A (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
ZA201500410B (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
IN2014DN10134A (pt)
ZA201500411B (en) Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2542 DE 24-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.